MetaCap

Prestige Consumer Healthcare (PBH) vs Arcus Biosciences (RCUS)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Prestige Consumer Healthcare (PBH) has outperformed Arcus Biosciences (RCUS) over the past year, losing 16.5% versus a loss of 29.2%. Over five years, PBH leads with a -12.0% price change compared with -66.3% for RCUS. Prestige Consumer Healthcare is the larger company by market cap ($2.35 billion vs $2.25 billion), about 1.0 times the size, while Arcus Biosciences is growing revenue faster (-4.3% vs -4.3%).

Prestige Consumer Healthcare converts more of its revenue into profit, with a net margin of 17.5% versus -142.9%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

PBH-16.48%RCUS-29.16%
+47%+7%-33%
Nov 21, 20251 yearNov 20, 2026
PBH-14.81%RCUS-67.15%
+60%-16%-92%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

PBH versus RCUS key metrics
MetricPBHRCUS
Share price$49.63$15.62
Market cap$2.35B$2.25B
1-day change+0.06%-1.01%
YTD return-19.55%-34.45%
1-year return-16.48%-29.16%
5-year return-12.02%-66.31%
P/E ratio (TTM)15.32—
Forward P/E9.76—
EPS (TTM)$3.24$-3.64
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$1.09B$247.00M
Revenue growth (YoY)-4.31%-4.26%
Net income (latest FY)$190.30M$-353.00M
Gross margin54.71%—
Operating margin28.42%-156.28%
Net margin17.48%-142.91%
52-week high$71.07$31.74
52-week low$41.77$15.56
Distance from 52-week high-30.17%-50.78%
Analyst consensusbuystrong_buy
Avg. price target upside+33.39%+162.48%
Average volume583.25K1.85M
Shares outstanding47.40M143.99M
Employees890601
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • PBH has outperformed RCUS by 12.7 percentage points over the past year.
  • Prestige Consumer Healthcare is more profitable, keeping 17.5 cents of every revenue dollar as net income versus -142.9 cents for Arcus Biosciences.

About Prestige Consumer Healthcare

PBH stock →

Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over the counter (OTC) health and personal care products in North America, Australia, and internationally. It operates in two segments, North American OTC Healthcare and International OTC Healthcare.

Health Care · Biotechnology: Pharmaceutical Preparations · 890 employees

About Arcus Biosciences

RCUS stock →

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody.

Health Care · Biotechnology: Pharmaceutical Preparations · 601 employees

PBH vs RCUS FAQ

Which is bigger, Prestige Consumer Healthcare or Arcus Biosciences?

Prestige Consumer Healthcare (PBH) is larger, with a market capitalization of $2.35B compared with $2.25B for Arcus Biosciences (RCUS).

Which stock has performed better over the past year, PBH or RCUS?

PBH returned -16.48% over the past 12 months, compared with -29.16% for RCUS (price return, excluding dividends). Past performance does not predict future results.

Are Prestige Consumer Healthcare and Arcus Biosciences in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons